MOSAIQUES and U.S. FDA describe detection of drug-induced side effects in early phase animal models

11-May-2009 - Drug-induced toxicity represents a significant problem in health care delivery: Over 100,000 people die per year from adverse effects of medications in the U.S. (Starfield, JAMA 2000, 284: 483-485). This has led to an intense awareness of drug-induced side effects, which may hamper the ...

mosaiques and U.S. FDA sign contract for collaboration in discovery and validation of biomarkers for assessment of drug toxicity

25-Feb-2009 - mosaiques diagnostics and therapeutics AG announced the signing of a collaborative agreement with the U.S. Food and Drug Administration. The aim of this collaborative project is the identification and validation of protein- and peptide biomarkers for drug toxicity in urine. Based on preliminary ...

Urine analysis enables cardiovascular risk assessment

13-Nov-2007 - Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. A vast amount of deaths and disabilities caused by CAD could be cut by an early diagnosis, enabling effective individual actions for preventing clinical events like acute myocardial infarction. Researchers ...

Worldwide standards for clinical proteome analyses

The dream of individual medicine gets the scientific basis

01-Mar-2007 - After the many pitfalls of the GENOMICS-era, the basis for worldwide standards for clinical proteome research aiming towards early detection of live-threatening diseases as well as evaluation of therapeutic success has been set. With the publication of suggested guidelines in PROTEOMICS - ...